These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24456794)

  • 1. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
    Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
    Tolcher A; Goldman J; Patnaik A; Papadopoulos KP; Westwood P; Kelly CS; Bumgardner W; Sams L; Geeganage S; Wang T; Capen AR; Huang J; Joseph S; Miller J; Benhadji KA; Brail LH; Rosen LS
    Eur J Cancer; 2014 Mar; 50(5):867-75. PubMed ID: 24440085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
    Bullock KE; Petros WP; Younis I; Uronis HE; Morse MA; Blobe GC; Zafar SY; Gockerman JP; Lager JJ; Truax R; Meadows KL; Howard LA; O'Neill MM; Broadwater G; Hurwitz HI; Bendell JC
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):465-74. PubMed ID: 21079958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
    BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
    Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
    Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
    Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
    Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
    Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
    Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
    Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
    Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
    Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
    Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
    Molife LR; Yan L; Vitfell-Rasmussen J; Zernhelt AM; Sullivan DM; Cassier PA; Chen E; Biondo A; Tetteh E; Siu LL; Patnaik A; Papadopoulos KP; de Bono JS; Tolcher AW; Minton S
    J Hematol Oncol; 2014 Jan; 7():1. PubMed ID: 24387695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
    Haura EB; Tanvetyanon T; Chiappori A; Williams C; Simon G; Antonia S; Gray J; Litschauer S; Tetteh L; Neuger A; Song L; Rawal B; Schell MJ; Bepler G
    J Clin Oncol; 2010 Mar; 28(8):1387-94. PubMed ID: 20142592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
    Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1.
    Leohr JK; Luffer-Atlas D; Luo MJ; DeBrota DJ; Green C; Mabry TE; Suico JG
    J Clin Pharmacol; 2018 Apr; 58(4):412-424. PubMed ID: 29178617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.